Home Tags SpringWorks Therapeutics
Tag: SpringWorks Therapeutics
The transaction also includes incremental tiered royalties on future net sales.
The gross proceeds to SpringWorks from the offering are expected to be $162 million.
Fuhrman previously served on the board of Stamford’s Loxo Oncology until its sale to Eli Lilly earlier this year.
The Stamford company says it plans to apply some of the proceeds from its $115 million IPO towards a Phase 3 study of a drug candidate for treating patients with tumors that occur in connective tissue.
"The fast track designation recognizes that desmoid tumors have a substantial impact on the lives of patients," said Saqib Islam, CEO of SpringWorks Therapeutics.